Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Mr. Pasternak brings decades of global pharmaceutical leadership experienceTransition further highlights transformation of the Board to lead ...
Fox News3d
Mike Johnson replaces powerful Intelligence Committee chairman after Russian nuclear threat warning
Speaker Mike Johnson is replacing Rep. Mike Turner as chairman of the House Intelligence Committee after a debacle that started with a warning about Russian space nuclear technology last year ...
ABC News2d
Speaker Johnson removes Mike Turner as Intel Committee Chairman
House Speaker Mike Johnson said the committee needs a "fresh start." Ohio Republican Rep. Mike Turner has been removed as the chairman of the House Intelligence Committee and will not serve in ...
New York Post5d
Prince Harry suffers setback as head of firm quits Travalyst after less than 2 years: ‘No surprise’
Prince Harry has suffered a setback as the first chairman of his eco-friendly firm Travalyst has quit. India Gary-Martin, who joined the company in 2023, left the position after less than two ...
New York Post6d
JPMorgan’s Jamie Dimon ‘likely’ to become chairman once he quits as CEO
JPMorgan boss Jamie Dimon said Sunday he would “likely” take over as chairman of the Wall Street giant when he eventually steps down as CEO. “That’s likely to happen. Again, that is up to ...
NBC News3d
Speaker Johnson removes Mike Turner as House Intelligence Committee chairman
WASHINGTON — Speaker Mike Johnson, R-La., has informed Rep. Mike Turner, R-Ohio, that he will no longer be chairman of the House Intelligence Committee, according to a GOP leadership source and ...
Context doses first patient in Phase 1 clinical trial evaluating CTIM-76
Context Therapeutics (CNTX) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6, or ...
Nasdaq4d
Context Therapeutics Doses First Patient in Phase 1 Trial of CTIM-76 for CLDN6-Positive Cancers
Context Therapeutics announces first patient dosed in Phase 1 trial of CTIM-76 for CLDN6-positive cancers. Initial data expected 2026. Context Therapeutics Inc. has announced the dosing of the ...
Morningstar4d
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
The Company anticipates sharing initial data for the CTIM-76 Phase 1 trial in the first half of 2026. “Dosing of the first patient in the CTIM-76 Phase 1 trial represents a key advancement of ...
Context Therapeutics Inc.: Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therap ...
manilatimes4d
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
The Company anticipates sharing initial data for the CTIM-76 Phase 1 trial in the first half of 2026. "Dosing of the first patient in the CTIM-76 Phase 1 trial represents a key advancement of our ...